Page last updated: 2024-09-05

deferasirox and Granulocytic Leukemia, Chronic

deferasirox has been researched along with Granulocytic Leukemia, Chronic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choi, CW; Kang, MH; Kim, DS; Na, YJ; Yoon, SY	1

Other Studies

1 other study(ies) available for deferasirox and Granulocytic Leukemia, Chronic

Article	Year
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. The Korean journal of internal medicine, 2016, Volume: 31, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Iron Chelating Agents; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction; Triazoles	2016

Article

Year

Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.

The Korean journal of internal medicine, 2016, Volume: 31, Issue:2

Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Iron Chelating Agents; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction; Triazoles

2016